News | June 30, 2023
Lupin achieves milestone for its phase 1 clinical stage MALT1 inhibitor program
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
Lupin has received US$ 25 million from AbbVie for initiation of Phase 1 clinical studies successfully
Sunrise is built on four elements i.e., Awareness, Screening & Diagnosis, Treatment, and Maintenance Support
Ayurveda is one of the most advanced sciences of its times
The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources for the goal of accelerating the evaluation of the respective companies’ assets, mirikizumab and Tremfya (guselkumab).
A First of its Kind Initiative in Mahbubnagar District for Medical Officers, ANM, Anganwadi workers for prevention of Thalassemia and Sickle Cell anemia as part of Antenatal screening of pregnant women project
The proposed initiative is conceptualised with an objective to identify, support, and promote innovative research ideas in healthcare research
Soluplus branded excipient play a critical role in enabling the drug development process for poorly soluble active pharmaceutical ingredients
With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
The voluntary program is the first time the FDA will allow excipient manufacturers to obtain review of certain novel excipients prior to their use in drug formulations.
Subscribe To Our Newsletter & Stay Updated
